Silence Therapeutics Plc (SLNCF)
4.00
0.00 (0.00%)
USD |
OTCM |
Sep 04, 16:00
Silence Therapeutics SG&A Expense (TTM) : 21.27M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 21.27M |
| March 31, 2026 | 21.69M |
| December 31, 2025 | 22.34M |
| September 30, 2025 | 25.89M |
| June 30, 2025 | 26.77M |
| March 31, 2025 | 28.19M |
| September 30, 2024 | 25.61M |
| June 30, 2024 | 24.60M |
| March 31, 2024 | 24.34M |
| Date | Value |
|---|---|
| December 31, 2023 | 25.62M |
| September 30, 2023 | 24.58M |
| June 30, 2023 | 25.16M |
| March 31, 2023 | 24.46M |
| December 31, 2022 | 24.36M |
| September 30, 2022 | 20.29M |
| June 30, 2022 | 13.44M |
| March 31, 2022 | 7.732M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Biodexa Pharmaceuticals Plc | 6.375M |
| NuCana Plc | 7.064M |
| Mereo BioPharma Group Plc | 19.44M |
| Compass Pathways Plc | 68.79M |
| HemoGenyx Pharmaceuticals Plc | 8.463M |